Literature DB >> 15864268

Rho kinase, a promising drug target for neurological disorders.

Bernhard K Mueller1, Helmut Mack, Nicole Teusch.   

Abstract

Rho kinases (ROCKs), the first Rho effectors to be described, are serine/threonine kinases that are important in fundamental processes of cell migration, cell proliferation and cell survival. Abnormal activation of the Rho/ROCK pathway has been observed in various disorders of the central nervous system. Injury to the adult vertebrate brain and spinal cord activates ROCKs, thereby inhibiting neurite growth and sprouting. Inhibition of ROCKs results in accelerated regeneration and enhanced functional recovery after spinal-cord injury in mammals, and inhibition of the Rho/ROCK pathway has also proved to be efficacious in animal models of stroke, inflammatory and demyelinating diseases, Alzheimer's disease and neuropathic pain. ROCK inhibitors therefore have potential for preventing neurodegeneration and stimulating neuroregeneration in various neurological disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15864268     DOI: 10.1038/nrd1719

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  197 in total

1.  Elaborate ligand-based modeling reveal new submicromolar Rho kinase inhibitors.

Authors:  Rand Shahin; Saja Alqtaishat; Mutasem O Taha
Journal:  J Comput Aided Mol Des       Date:  2011-12-14       Impact factor: 3.686

Review 2.  Applications of molecular imaging.

Authors:  Craig J Galbán; Stefanie Galbán; Marcian E Van Dort; Gary D Luker; Mahaveer S Bhojani; Alnawaz Rehemtulla; Brian D Ross
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

Review 3.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors:  Rebecca K Donegan; Raquel L Lieberman
Journal:  J Med Chem       Date:  2015-09-25       Impact factor: 7.446

Review 4.  Drug therapy for chronic idiopathic axonal polyneuropathy.

Authors:  Janna Warendorf; Alexander Fje Vrancken; Ivo N van Schaik; Richard Ac Hughes; Nicolette C Notermans
Journal:  Cochrane Database Syst Rev       Date:  2017-06-20

5.  HIV-1 Tat activates a RhoA signaling pathway to reduce NMDA-evoked calcium responses in hippocampal neurons via an actin-dependent mechanism.

Authors:  Kelly A Krogh; Elizabeth Lyddon; Stanley A Thayer
Journal:  J Neurochem       Date:  2014-09-18       Impact factor: 5.372

Review 6.  Can regenerating axons recapitulate developmental guidance during recovery from spinal cord injury?

Authors:  Noam Y Harel; Stephen M Strittmatter
Journal:  Nat Rev Neurosci       Date:  2006-08       Impact factor: 34.870

7.  CD151 Alleviates Early Blood-Brain Barrier Dysfunction After Experimental Focal Brain Ischemia in Rats.

Authors:  Wendeng Xu; Ceshu Gao; Jian Wu
Journal:  Cell Mol Neurobiol       Date:  2020-04-13       Impact factor: 5.046

8.  Suppressive effect of Rho-kinase inhibitors Y-27632 and fasudil on spike-and-wave discharges in genetic absence epilepsy rats from Strasbourg (GAERS).

Authors:  Nihan Çarçak; Melis Yavuz; Tuğba Eryiğit Karamahmutoğlu; Akif Hakan Kurt; Meral Urhan Küçük; Filiz Yılmaz Onat; Kansu Büyükafsar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-08-02       Impact factor: 3.000

9.  Two functional polymorphisms of ROCK2 enhance arterial stiffening through inhibiting its activity and expression.

Authors:  Yi-Chu Liao; Ping-Yen Liu; Hsiu-Fen Lin; Wen-Yi Lin; James K Liao; Suh-Hang H Juo
Journal:  J Mol Cell Cardiol       Date:  2014-12-03       Impact factor: 5.000

10.  A molecular mechanism for ibuprofen-mediated RhoA inhibition in neurons.

Authors:  John Dill; Ankur R Patel; Xiao-Li Yang; Robert Bachoo; Craig M Powell; Shuxin Li
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.